{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"12.9","value":"8.50"},{"groupId":"OG002","lowerLimit":"4.1","upperLimit":"40.1","value":"10.83"},{"groupId":"OG003","lowerLimit":"7.9","upperLimit":"31.9","value":"12.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Time to response (TTR) was defined as the time from first dose of study treatment to the first documentation of response (either partial response (PR) or complete response (CR)).\n\nCR:\n\n* Negative immunofixation on the serum and urine.\n* Disappearance of any soft tissue plasmacytomas.\n* Less than 5% plasma cells in the bone marrow.\n\nPR:\n\n* At least a 50% reduction in serum M-protein.\n* Reduction in 24-hour urinary M-protein by at least 90% or to less than 200 mg per 24 hours.\n* For patients with non-secretory myeloma, a reduction of at least 50% in the size of soft tissue plasmacytomas is required.","dispersionType":"Full Range","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"paramType":"MEAN","populationDescription":"All treated participants in the Efficacy Evaluable population with a best response of PR or CR.","reportingStatus":"POSTED","timeFrame":"From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Weeks"}